19
2020-07
真人直营投注网站 (“Kintor Pharmaceutical” or the “Company”, stock code 9939.HK) announced the completion of patients enrolment according to the clinical protocol for phase II clinical trials (NCT03899467) of Proxalutamide (GT0918) in the United States for treating metastatic castration-resistant prostate cancer (“mCRPC”).
14
2020-07
Kintor to Colloborate with Applied Biology in COVID-19 Study of Proxalutamide
Jiangsu, China, July 12, 2020 - Suzhou Kintor Pharmaceutical, Inc. a wholly-owned subsidiary of 真人直营投注网站 (“Kintor Pharma”, 9939.HK), and Applied Biology, Inc. entered into a clinical trial research agreement ("Research Agreement"), pursuant to which Suzhou Kintor collaborates with Applied Biology to conduct research for Proxalutamide (GT0918) as a treatment for the novel coronavirus disease ("COVID-19"). We believe that this study is an innovative attempt to use anti-androgens as a possible treatment to devastating COVID-19 worldwide pandemic .
28
2020-06
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy
真人直营投注网站 announced that it has signed a strategic cooperation framework agreement with JD Pharmacy, the pharmaceutical retail channel under JD Health, in a concerted effort to create a patient-centred online innovative healthcare ecosystem. JD Pharmacy will utilise its abundant traffic and resources and strong technological and supply chain capabilities to assist Kintor Pharmaceutical in the marketing and sales of the innovative External use drug KX-826.
22
2020-05
Kintor Pharmaceutical successfully listed on HKEX today
真人直营投注网站 (Stock Code:9939.HK) has successfully been listed on the Main Board of the Stock Exchange of Hong Kong Limited on 22,May 2020.
19
2020-05
On the last day of 2019, Kintor’s application for a HKEX listing had attracted industry attention. It was reported that with this Hong Kong stock IPO listing on May 22nd 2020 and the global sale of 92
09
2020-05
In 2008, as the first group of pioneers to return to China to conduct research on small molecule anticancer drugs, Dr. Youzhi Tong said, there were not many companies doing new drug research and devel
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn